UPDATE: Onxigene Says Trial of ZYBRESTAT Achieved Primary Efficacy Endpoint
March 11, 2014 at 15:42 PM EDT
OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced ...